PA
AKBA icon

Profund Advisors’s Akebia Therapeutics AKBA Stock Holding History

Profund Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-147,109
Closed -$204K – 1180
2026
Q1 		$204K Sell
147,109
-37,571
-20% -$51.6K 0.01% 1012
2025
Q4 		$297K Buy
184,680
+80,706
+78% +$169K 0.01% 878
2025
Q3 		$284K Buy
103,974
+48,912
+89% +$163K 0.01% 761
2025
Q2 		$200K Buy
55,062
+10,140
+23% +$27.9K 0.01% 907
2025
Q1 		$86.3K Buy
44,922
+7,252
+19% +$14.8K ﹤0.01% 963
2024
Q4 		$71.6K Buy
+37,670
New +$65.4K ﹤0.01% 1089

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Profund Advisors's AKBA Position: Q2 2026 in Review

Profund Advisors sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 147,109 shares — an estimated $204K sold.

Profund Advisors first reported a position in AKBA in Q4 2024 and held it in 6 quarters. The position peaked at $297K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Profund Advisors reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Profund Advisors sold 147,109 Akebia Therapeutics shares in Q2 2026, an estimated $204K.
  • Profund Advisors first reported a position in Akebia Therapeutics in Q4 2024 and held it in 6 quarters.
  • Profund Advisors's Akebia Therapeutics position peaked at $297K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.